[Microstructural retinal changes after pharmacological vitreolysis with ocriplasmin-an SD-OCT supported analysis].

CONCLUSIONS: Ocriplasmin is a substantial minimal invasive option in the therapy of VMT with or without small FTMH. Nevertheless, there seem to be some specific ocriplasmin-associated risks, although usually transient. Severe complications like retinal detachment are rare but exist. Therefore, every indication of ocriplasmin should be considered carefully.
PMID: 31346704 [PubMed - as supplied by publisher]

Source: Der Ophthalmologe - July 25, 2019 Category: Opthalmology Authors: Groselli S, Wehrmann K, Rüther K, Feucht N, Lohmann CP, Maier M Tags: Ophthalmologe Source Type: research